Quoin Pharmaceuticals, Ltd.
QNRX
$6.97
-$0.18-2.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 8.78% | 19.24% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.67% | 13.51% | |||
| Operating Income | -6.67% | -13.51% | |||
| Income Before Tax | -7.47% | -14.93% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -7.47% | -14.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.47% | -14.93% | |||
| EBIT | -6.67% | -13.51% | |||
| EBITDA | -6.71% | -13.59% | |||
| EPS Basic | -7.39% | -1.26% | |||
| Normalized Basic EPS | -7.40% | -1.27% | |||
| EPS Diluted | -7.39% | -1.26% | |||
| Normalized Diluted EPS | -7.40% | -1.27% | |||
| Average Basic Shares Outstanding | 0.07% | 13.50% | |||
| Average Diluted Shares Outstanding | 0.12% | 13.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||